E-mobility startup Kazam has raised $8 million in its Series A3 funding round led by Vertex Ventures Southeast Asia and India. In another development, oncology startup 4baseCare has raised $6 million in its Series A funding round led by Yali Capital and other investors.
Vertex leads $8m funding in Kazam
Bengaluru-based e-mobility startup Kazam has raised $8 million in its Series A3 funding round, led by Vertex Ventures Southeast Asia and India. The funding round also saw participation from Avaana Capital, Alteria Capital, and several other notable investors, the startup said in a statement.
With the fresh infusion, Kazam plans to bolster its technology and product teams, enhance its platform offerings and expand its market presence. “We have grown our monthly transactions 10x and EV km fuelled in the last 12 months. This investment will enable us to accelerate our growth, innovate further, and maintain our leadership position in the e-mobility sector,” said Akshay Shekhar, Co-Founder & CEO, Kazam.
Kazam enables a diverse range of vehicles including two-wheelers, commercial electric vehicles (CEV), three-wheelers, and city buses, serving over 25,000 charging points. It recently launched a first-of-its-kind LEV-DC, a fast charging option for electric two- and three-wheelers that it claims can charge an electric scooter up to 80% in 20 minutes.
4baseCare raises $6m
Bengaluru-based 4baseCare, which offers oncology solutions using advanced genomics and digital health technology, has raised $6 million in its Series A funding round led by Yali Capital and other investors.
The funding will be used to enhance product offerings and to scale up operations for further expansion across India, as well as other countries in Asia and the Middle East, the startup said in a statement.
“4baseCare was founded to address the critical genomic data gap in cancer care. Our journey from developing TARGT Indiegene to impacting the lives of over 10,000 patients has been a fulfilling experience. The success of our test and our growth over the years is a result of the exceptional support from our investors and the invaluable insights from our advisory board. This funding will further enable us to enhance our product offerings and advance our mission of making personalised cancer care accessible to millions,” said Hitesh Goswami, CEO and co-founder, 4baseCare.
Over the next few months, 4baseCare will set up genomics laboratories in the Philippines, Nepal, and Dubai. Additionally, they will focus on building genomics and digital health solutions, focusing on data analytics, improved clinical insights, and data-driven treatment recommendations.
